Amgen Hiding Biosimilar Info, Genentech Suit Says

Law360, New York (February 16, 2017, 8:32 PM EST) -- Amgen is hypocritically withholding information about its proposed biosimilar of cancer drug Avastin and thereby undercutting potential patent litigation, Genentech charged in a complaint filed Wednesday in Delaware federal court.

Genentech Inc.’s complaint accuses Amgen Inc. of short-circuiting a section of the Biologics Price Competition and Innovation Act known as the “patent dance.” The dance directs biosimilar makers to disclose approval applications and “other information” about manufacturing, but Amgen has only divulged its application, according to Genentech.

That amounts to “ignoring the express statutory language” of...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Genentech, Inc. v. Amgen Inc.


Case Number

1:17-cv-00165

Court

Delaware

Nature of Suit

Other Statutory Actions

Judge

Unassigned Judge

Date Filed

February 15, 2017

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.